Controversies in Systemic Lupus Erythematosus 2021: Changing the Paradigm in the Management of Lupus Nephritis.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
ppublish
Résumé
Lupus nephritis (LN) affects about a third of patients with systemic lupus erythematosus. Although the use of conventional therapy has significantly improved the prognosis of LN, the response to treatment remains suboptimal, with high rates of relapse and the occurrence of end-stage kidney disease. The implementation of new diagnostic and treatment strategies aimed at improving these outcomes represents a necessary paradigm shift in the management of LN.Herein, we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the virtual congress of the Pan American League of Associations for Rheumatology (PANLAR) and which was organized by the PANLAR Lupus Study Group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on August 15, 2021.
Identifiants
pubmed: 35616510
doi: 10.1097/RHU.0000000000001859
pii: 00124743-202206000-00009
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-233Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
S.V.P., A.E., M.G., B.A.P.-E., and G.S.A have no conflicts of interest to declare. R.F. has received consulting fees from GSK and Aurinia Pharmaceuticals. F.H. has received consultant fees from GSK, Astra-Zeneca, and Idorsia. B.H.R. has received consulting fees from GSK and Aurinia Pharmacetuicals. G.J.P.-E. is a speaker, is a consultant, and received grants from Pfizer, Janssen, GSK, Sandoz, and Sanofi.
Références
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis . 2020;79:713–723.
Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol . 2016;68:1432–1441.
Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol . 2015;67:1305–1313.
Tamirou F, D'Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis . 2016;75:526–531.
Tamirou F, Lauwerys BR, Dall'Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci Med . 2015;2:e000123.
Mackay M, Dall'Era M, Fishbein J, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol . 2019;71:411–419.
Ugolini-Lopes MR, Seguro LPC, Castro MXF, et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med . 2017;4:e000213.
Reátegui-Sokolova C, Ugarte-Gil MF, Harvey GB, et al. Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open . 2020;6:e001299.
Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant . 2017;32:1338–1344.
Parodis I, Adamichou C, Aydin S, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) . 2020;59:3424–3434.
ReBioLup—A prospective repeat kidney biopsy endeavour 2021. Available at: http://rebiolup.com/ . Accessed August 29, 2021.
Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis . 2012;60:62–73.
Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med . 2018;6(Suppl 1):S41.
Moroni G, Depetri F, Ponticelli C. Lupus nephritis: when and how often to biopsy and what does it mean? J Autoimmun . 2016;74:27–40.
Pagnini F, Cervi E, Maestroni U, et al. Imaging guided percutaneous renal biopsy: do it or not? Acta Biomed . 2020;91(8-S):81–88.
Sun YS, Sun IT, Wang HK, et al. Risk of complications of ultrasound-guided renal biopsy for adult and pediatric patients with systemic lupus erythematosus. Lupus . 2018;27:828–836.
Jordan N, Chaib A, Sangle S, et al. Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) . 2014;66:725–731.
Petri M, Barr E, Magder LS. Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis. J Rheumatol . 2021;48:222–227.
Gómez-Puerta JA, Pons-Estel GJ, Quintana R. A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus . 2021;961203320988586.
Dasari S, Chakraborty A, Truong L, et al. A systematic review of interpathologist agreement in histologic classification of lupus nephritis. Kidney Int Rep . 2019;4:1420–1425.
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med . 2020;383:1117–1128.
Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int . 2022;101:403–413.
Furie R, Rovin BH, Houssiau F, et al. POS0689 A 6-month open-label extension study of the safety and efficacy of intravenous belimumab in patients with lupus nephritis. Ann Rheum Dis . 2021;80(Suppl 1):591–592.
Rovin BH, Solomons N, Pendergraft WF 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int . 2019;95:219–231.
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet . 2021;397:2070–2080.
Praga M. Therapeutic measures in proteinuric nephropathy. Kidney Int Suppl . 2005;S137–S141.
Schonenberger E, Ehrich JH, Haller H, et al. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant . 2011;26:18–24.
Campbell KN, Tumlin JA. Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol . 2018;47(Suppl 1):14–29.
Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int . 2002;61:1475–1485.
Krassanairawiwong K, Charoenpitakchai M, Supasyndh O, et al. Revised ISN/RPS 2018 classification of lupus renal pathology predict clinical remission. Int Urol Nephrol . 2021;53:1391–1398.
Hachiya A, Karasawa M, Imaizumi T, et al. The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis. Sci Rep . 2021;11:1525.